# Pizarra — PT-pseudo_25007bb807d7 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_25007bb807d7
Task: 1

Encounter: Urology - outpatient on 19 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 17.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.462 ng/mL²
  - PSA velocity: 1.29 ng/mL/yr
  - Prior PSA: 16.1 ng/mL
  - Prostate volume: 36.82 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.85766834 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 17 ng/mL. PI-RADS 5. PSAD 0.46. Prostate volume 37 mL. csPCa 0.86.

Vitals: weight 83 kg, height 193 cm, BMI 22.3, BP 122/68 mmHg, HR 74 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2015).

Chief complaint: Persistent prostate-specific antigen elevation prompted mpMRI scheduling.

History: A 61-year-old office administrator entered the clinical pathway after a sustained prostate-specific antigen rise spanning three years. Lower urinary tract symptoms are minimal, scoring four on the IPSS questionnaire, while haematuria, pelvic discomfort, and unexplained weight loss are absent. Smoking history totals 16 pack-years, with cessation occurring in 2015; weekend hiking and roughly 11 units of alcohol weekly characterize his routine. He resides with his wife, who acts as his primary contact. Recent ophthalmological intervention involved uneventful cataract surgery, necessitating large-print materials for correspondence. Cardiovascular status remains stable, confirmed by a cardiology review in autumn 2024 that required no active interventions. There is a complete absence of prior urological procedures, comorbid conditions, or current medications.

Physical examination: DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. General inspection shows a well-nourished individual with stable vital signs, alongside an absence of palpable lymphadenopathy or hepatosplenomegaly.

Patient info: office administrator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 11 units / week; exercise Hiking on weekends; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024).
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.81 +/- 0.07   (95% CI 0.66-0.95)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.07  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.70 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend and velocity beyond the headline value?
  - previous_notes (get_previous_notes) -> What is the prior management context, including prior grade and surveillance pathway?

This case hinges on the detailed findings from the mpMRI, the PSA trajectory, and the prior management context to confirm the guideline criterion for biopsy. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (17.0 ng/mL), PI-RADS (5), PSA density (0.462 ng/mL²), prostate volume (36.82 mL), and csPCa predicted probability (0.85766834). It cannot weigh the qualitative information from the mpMRI prose, the PSA velocity (1.29 ng/mL/yr), or the context provided by the agenda items regarding prior notes or specific lab values.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests a high probability of biopsy (0.81), but the guideline track record is based on a cohort where the decision hinges on specific MRI findings (PI-RADS 3 or higher) and the patient's biopsy status. The prior does not account for the fact that the guideline criterion is met, but it cannot assess if the specific PI-RADS 5 finding is the sole driver, or if other factors (like PSA velocity or DRE) might temper the decision, which the prior ignores. The high aleatoric uncertainty (H=0.70) suggests the model struggles with the data distribution, meaning the suggestion might be highly sensitive to unobserved variables.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - What is the serial PSA trend and velocity beyond the headline value?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion, and the track record for this criterion is 24/24 matches in the labelled cohort.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_25007bb807d7", "radiology_report": "Subject: mpMRI Prostate\nDate: 15 January 2025\nFacility: Amsterdam UMC (VUmc location)\n\nClinical indication: Evaluation of elevated PSA (17.0 ng/mL) and clinical suspicion of malignancy.\n\nFINDINGS: The gland measures 36.82 mL in total volume. T2-weighted sequences highlight a distinct, 18 mm hypointense focus within the right peripheral zone, spanning the base to mid-gland. Diffusion-weighted imaging reveals pronounced restriction with corresponding ADC hypointensity. Dynamic contrast-enhanced phases demonstrate early, focal arterial enhancement localized to the lesion. There is no evidence of extraprostatic extension, seminal vesicle invasion, or pelvic lymphadenopathy.\n\nIMPRESSION: PI-RADS 5 lesion in the right peripheral zone. Prostate volume 36.82 mL yielding a PSA density of 0.462 ng/mL/mL. csPCa predicted probability 0.85766834"}
get_psa_trend
{"case_id": "PT-pseudo_25007bb807d7", "psa_trend": [{"date": "Jun 2022", "val": 5.7}, {"date": "Jan 2023", "val": 11.3}, {"date": "Sep 2023", "val": 15.4}, {"date": "May 2024", "val": 3.1}, {"date": "Jan 2025", "val": 17.0}]}
get_previous_notes
{"case_id": "PT-pseudo_25007bb807d7", "previous_notes": [{"date": "21 Sep 2024", "author": "Dr. R. van den Berg (GP)", "text": "The patient was reviewed following a PSA reading of 16.1 ng/mL in May 2024. Symptoms remain minimal with an IPSS score of four, and cross-sectional imaging was arranged to clarify the aetiology of the persistent elevation. A routine urinalysis was unremarkable ahead of the planned urology visit."}, {"date": "25 Jan 2024", "author": "Dr. R. van den Berg (GP)", "text": "Follow-up consultation regarding a PSA of 15.3 ng/mL obtained in September 2023. The gentleman reports only mild voiding frequency without nocturia or urgency, and a repeat PSA was arranged to monitor the trajectory."}]}
NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda did not explicitly require it, and retrieving it would not change the decision based on the required documents.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion in the right peripheral zone.
- psa_trend: PSA velocity of 1.29 ng/mL/yr, with a recent rise to 17.0 ng/mL.
- previous_notes: Patient was reviewed following a PSA of 16.1 ng/mL and cross-sectional imaging was arranged.
AGAINST sampling this patient now:
- previous_notes: No prior biopsy grade is documented.
- previous_notes: Patient is not explicitly stated to be on an active surveillance protocol requiring a protocol biopsy.
WHERE THIS LEANS
The combined evidence strongly supports proceeding with a biopsy due to the high-risk PI-RADS 5 finding and the rising PSA velocity.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 5 finding from the MRI and the rising PSA velocity, strongly supports the guideline criterion for biopsy.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The guideline criterion mandates biopsy for a PI-RADS 5 lesion, which was explicitly retrieved from the mpMRI report. This finding, combined with the rising PSA velocity of 1.29 ng/mL/yr, strongly supports the protocol recommendation. The statistical prior also suggested biopsy, and the retrieved evidence confirmed the clinical pathway.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
